(2S)-5-carbamimidamido-N-[(1S)-1-carbamoyl-2-phenylethyl]-2-[(3R,5S,7s)-adamantan-1-ylformamido]pentanamide; trifluoroacetic acid

• ChemBase编号: 154322
• 分子式: C28H39F3N6O5
• 平均质量: 596.6416696
• 单一同位素质量: 596.29340304
• SMILES: c1ccc(cc1)C[C@H](NC(=O)[C@@H](NC(=O)[C@@]12C[C@H]3C[C@@H](C1)C[C@H](C2)C3)CCCNC(=N)N)C(=O)N.C(=O)(O)C(F)(F)F
• Canonical SMILES: OC(=O)C(F)(F)F.NC(=N)NCCC[C@@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)NC(=O)[C@]12C[C@@H]3C[C@@H](C2)C[C@@H](C1)C3
• InChI: InChI=1S/C26H38N6O3.C2HF3O2/c27-22(33)21(12-16-5-2-1-3-6-16)31-23(34)20(7-4-8-30-25(28)29)32-24(35)26-13-17-9-18(14-26)11-19(10-17)15-26;3-2(4,5)1(6)7/h1-3,5-6,17-21H,4,7-15H2,(H2,27,33)(H,31,34)(H,32,35)(H4,28,29,30);(H,6,7)/t17-,18+,19-,20-,21-,26-;/m0./s1
• InChIKey: GPVFYPYIOXHDCU-CFIUKZCSSA-N

名称和登记号

名称

• IUPAC标准名: (2S)-5-carbamimidamido-N-[(1S)-1-carbamoyl-2-phenylethyl]-2-[(3R,5S,7s)-adamantan-1-ylformamido]pentanamide; trifluoroacetic acid
• IUPAC传统名: (2S)-5-carbamimidamido-N-[(1S)-1-carbamoyl-2-phenylethyl]-2-[(3R,5S,7s)-adamantan-1-ylformamido]pentanamide; trifluoroacetic acid
• 别名: 1-Adamantanecarbonyl-Arg-Phe-NH2 trifluoroacetate salt; RF9 trifluoroacetate salt

登记号

• CAS号: 876310-60-0(freebase)
• PubChem SID: 162248461
• PubChem CID: 71311841

理论计算性质

• Acid pKa: 12.491646
• 质子受体: 6
• 质子供体: 6
• LogD (pH = 5.5): -1.1695342
• LogD (pH = 7.4): -1.1652054
• Log P: 0.9407474
• 摩尔折射率: 142.8501 cm^3
• 极化性: 51.61889 Å^3
• 极化表面积: 163.19 Å^2
• 可自由旋转的化学键: 12
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: H2O: soluble20 mg/mL

安全信息

• 德国WGK号: 3
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• 保存温度: -20°C

产品相关信息

• 纯度: ≥97% (HPLC)
• Empirical Formula (Hill Notation): C26H38N6O3 · xC2HF3O2

详细说明

Sigma Aldrich - R4282

Biochem/physiol Actions
RF9 is a neuropeptide FF receptor antagonist. NPFF is a member of the FMRFamide (Phe-Met-Arg-PheNH2) family of neuropeptides, which are implicated in nociception and regulation of opioid analgesia. NPFF exhibits antiopioid activity (hyperalgesia). NPFF antagonists are expected to improve the therapeutic efficacy of opioids for treatment of chronic pain. The affinity of RF9 for NPFF1R and NPFF2R is 58 and 75 nM, respectively. RF9 acts as a potent competitive antagonist of NPFF at NPFF2R RF9 exhibits no agonist activity in GTPgS assays.